The company reported $616.5 million in fourth quarter sales, an increase of 124.6%, and full year sales of $1.6 billion, a 53.3% increase over the prior year, according to a news release. Globus Medical has also maintained its 2024 guidance range of $2.45 billion to $2.5 billion.
This year will be the first full year Globus Medical will be operating under its merger with NuVasive. In 2024, the company is anticipating the launch of a flagship knee robot.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
